OR WAIT null SECS
CluePoints, a provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, announced 183 studies across 22 sponsor and CRO organizations have taken advantage of CluePoints complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trials. Launched in April in the wake of COVID-19, the support package includes an online Risk Assessment and Control solution that can be leveraged for performing risk planning and mitigation activities addressing inherent risks during this crisis.
With sponsors and CROs facing a myriad of new recommendations and guidelines issued by the FDA, EMA, PMDA, MHRA and other local agencies due to coronavirus, the complimentary support package was offered to sponsors and CROs to keep up with the need to assess and control risk on new and ongoing studies, with documentation and audit trails even more important in this highly dynamic environment.
CluePoints has been commissioned to provide deeper analytical support to a further 135 studies.
Commenting on the support package, Patrick Hughes, Co-Founder and Chief Commercial Officer of CluePoints said, “We have also seen a significant increase in existing clients stepping up their data analysis to ensure early detection of issues needing urgent attention.”
In addition, CluePoints solutions have also been utilized in over 12 high-profile specific COVID-19 vaccine studies with leading pharma sponsors in conjunction with their top five CRO development partners.